Latest Sumatriptan Stories
Researchers are developing a novel prochlorperazine nasal spray formulation as a potential new treatment for migraines. CHICAGO, Jan.
--Company Plans to Complete a New Human Factor Validation Study and Respond to the CRL in the First Half of Calendar 2015-- ALISO VIEJO, Calif., Nov.
Despite the Continued Launch of Generics, the Migraine Market Will Grow by over $2 Billion from 2013 to 2023, According to Findings from Decision Resources BURLINGTON, Mass., Nov.
ALISO VIEJO, Calif., Nov. 7, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S.
ALISO VIEJO, Calif., Oct.
ALISO VIEJO, Calif., June 24, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the safety and efficacy of AVP-825, a Breath-Powered(TM)
AVP-825, Using OptiNose's Patented Bi-Directional(TM) Breath Powered(TM) Technology for Intranasal Delivery of Low-dose Sumatriptan, Demonstrates Greater Reduction in Migraine Pain Compared to the
--Migraine Sufferers Achieved Greater Rates of Pain Relief and Pain Freedom Within 30 Minutes with AVP-825 Treatment Compared with Oral Sumatriptan Treatment-- ALISO VIEJO, Calif.,
-Addition of product to Specialty Pharmaceuticals portfolio expected to be immediately accretive to adjusted diluted earnings per share DUBLIN, May 19, 2014 /PRNewswire/ -- Endo International
New Data Demonstrate that NUEDEXTA® may Provide Early PBA Symptom Remission ALISO VIEJO, Calif., April 28, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced
- In medieval musical notation, a sign or neume denoting a shake or trill.